Sergey Nivens / Shutterstock.com
Obviousness-type double patenting is a serious consideration that patent owners should keep in mind during the examination of an application or in performing due diligence on a patent portfolio, says MaryAnne Armstrong.
The April 22, 2014 decision in Gilead Sciences, Inc v Natco Pharma Inc (Gilead) emphasises that obviousness-type double patenting (ODP) is a concern not just during the examination of a patent before the US Patent and Trademark Office (USPTO) but is a viable basis for invalidating an issued patent despite the presumption of validity that a patent has under 35 USC §282. In the case, Gilead owned two patents: the ‘483 and the ‘375. After being sued for infringement of the ‘483 patent, Natco asserted that the claims of the ‘483 patent were invalid for ODP as being obvious given the claims of the ‘375 patent.
Unlike statutory double patenting under 35 USC §101 (stating in the singular that an inventor “may obtain a patent”, emphasis added), ODP is based on a judicially created doctrine that is intended to prevent the inappropriate extension of the patent term given to an invention by prohibiting claims in a second patent that are not patentably distinct from the claims in a first patent.
There are two ways to address an ODP rejection. As a first option, an ODP rejection can be addressed by showing that the claims in the respective patents or applications are not obvious over each other, either by amending the claims or through appropriate arguments. Alternatively, a terminal disclaimer may be filed: the term of the later-expiring application is disclaimed so that the two patents expire on the same date. Typically with an ODP rejection, if there are two pending applications, the examiner will reject the later-filed (and later-issued) application as the later-filed application will have a later expiration date.
Life Sciences Intellectual Property Review (LSIPR) tracks the increasing challenges for intellectual property specialists in the rapidly evolving world of life sciences. From gene patents to stem cell research, we provide the very best news and analysis.
To continue reading this article and to access 4,500+ articles, our digital magazines and special reports published for LSIPR subscribers only then you will need a subscription.
If you are already subscribed please login.
Official LSIPR subscribers include:
Allen & Overy
Arnold & Siedsma
Birch, Stewart, Kolasch & Birch LLP (BSKB)
Carpmaels & Ransford
European Patent Office
George Washington Law School
Kirkland & Ellis International LLP
Marks & Clerk
NiKang Therapeutics Inc.
Powell Gilbert LLP
Procopio, Cory, Hargreaves & Savitch LLP
The United States Patent and Trademark Office (USPTO)
World Intellectual Property Office
obviousness, double patenting, USPTO, patent infringement